Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Harbour BioMed Reports Successful Phase I Trial of Autoimmune Treatment

publication date: Feb 21, 2020

Harbour BioMed, a Suzhou-Shanghai biopharma, reported that HBM916, a fully human anti-FcRn monoclonal antibody aimed at autoimmune disorders, showed an "excellent" safety profile in a Hong Kong Phase I study. The candidate also reduced IgC levels, its target, though HBM did not release specific data. HBM will begin clinical trials of HBM916 that enroll patients with several autoimmune diseases, including adult immune thrombocytopenia, myasthenia gravis, Grave’s ophthalmopathy and neuromyelitis optica spectrum disorder. In 2017, HBM acquired Greater Chins rights for two biologic drugs, including HBM916, from Korea's HanAll Biopharma in an $81 million deal. More details....

Stock Symbol: (KS: 009420)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

ChinaBio® Events

ChinaBio Partnering Forum 2020

Content Availbalble Until Dec. 21, 2020